サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1753431

チクングニア熱の世界市場

Chikungunya Fever

出版日
ページ情報
英文 377 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
チクングニア熱の世界市場
出版日: 2025年06月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 377 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

チクングニア熱の世界市場は2030年までに6億7,070万米ドルに達する見込み

2024年に4億7,810万米ドルと推定されるチクングニア熱の世界市場は、分析期間2024-2030年にCAGR 5.8%で成長し、2030年には6億7,070万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるELISAベースのアッセイ診断は、CAGR 6.5％を記録し、分析期間終了までに4億680万米ドルに達すると予測されます。血清学的検査診断分野の成長率は、分析期間中CAGR 4.9％と推定されます。

米国市場は1億3,030万米ドルと推定、中国はCAGR9.3％で成長予測

米国のチクングニア熱市場は、2024年に1億3,030万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.3%で推移し、2030年には1億3,670万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と5.8%と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界のチクングニア熱市場- 主要動向と促進要因のまとめ

チクングニア熱が公衆衛生の主要課題として再燃しているのはなぜか？

チクングニア熱は、かつては散発的な熱帯病と考えられていましたが、近年、媒介蚊であるイエネコの急速な蔓延と世界の気温上昇により、世界の健康上の主要課題として再浮上しています。当初はアフリカとアジアの一部に限られていた感染症が、現在では南米、カリブ海諸国、さらには欧州や米国の一部でも発生しています。このように地理的な範囲が拡大しているのは、都市化、世界の旅行の増加、気候変動が、ウイルスの伝播と蚊の個体群の通年生存を促進する要因となっていることが主な原因です。チクングニア熱高熱、関節痛、疲労、発疹を特徴とするこの病気は、特に高齢者では、慢性的な関節炎症状が何ヶ月も続くことがあります。死亡率は低いもの、生産性の低下、ヘルスケアコスト、長期的な罹患率の点で、この病気の負担は大きいです。感染地域の公衆衛生システムは、サーベイランス、蚊の駆除プログラム、公衆啓発キャンペーンを強化する必要に迫られています。アウトブレイクの頻度と規模が拡大するにつれ、診断薬、治療薬、ワクチン開発の緊急性は世界・ヘルス・エコシステム全体で高まっています。

診断とサーベイランスの革新は疾病管理を強化するか？

はい、診断と疫学の進歩は、チクングニア熱の状況を一変させ始めています。臨床症状や血清学に基づく従来の診断では、デング熱やジカ熱のような疾患と重複することが多く、正確な同定が持続的な課題となっています。しかし、現在ではRT-PCRのような分子診断法が広く採用されるようになり、病気の初期のウイルス感染段階で正確な検出ができるようになっています。さらに、チクングニアと他のアルボウイルスを区別できるポイント・オブ・ケア検査やマルチプレックス・アッセイの開発により、アウトブレイク環境における症例管理や資源配分が改善されつつあります。地理情報システム（GIS）、AIを活用した予測モデリング、ドローンを使った蚊のサーベイランスも、政府やNGOがホットスポットを特定し、流行する前に発生を予測するために活用しています。流行地域では、モバイルヘルス（mヘルス）プラットフォームが、症状発現、治療効果、患者の経過観察の追跡に役立っており、患者ケアとデータ収集の両方を強化しています。低・中所得国においてデジタル・ヘルス・インフラが改善されるにつれて、こうした技術革新は、特に資源に制約のある環境において、タイムリーな介入と封じ込めの取り組みにおいてさらに重要になると思われます。

ワクチン開発と治療研究は市場展望をどのように形成しているか？

チクングニアに対する認可されたワクチンや特異的な抗ウイルス治療薬が存在しないため、バイオテクノロジー企業、大学、官民パートナーシップの間で、この重大なギャップを埋めるための世界の競争に拍車がかかっています。現在、いくつかのワクチン候補がさまざまな開発段階にあり、そのうちのいくつかは第III相臨床試験段階にあります。その中には、従来の不活化プラットフォームを利用したものもあれば、ウイルス様粒子（VLP）やmRNAのような最先端技術を活用したものもあります。疫病対策イノベーション連合（CEPI）とWHOは、予防対策に対する世界の需要の高まりを見込んで、迅速な開発と規制経路の確立を積極的に支援しています。治療薬の面では、抗炎症薬や抗ウイルス薬の再利用に関する調査が進行中であり、高リスク患者に対してはモノクローナル抗体療法が検討されています。特に流行地域では、植物や天然物の研究も、代替的な症状管理アプローチに貢献しています。実用的なワクチンが承認されれば、政府の予防接種プログラムや世界の保健機関が、特に高負担地域において大量採用を推進すると予想されます。パンデミックへの備えやウイルス感染症への対応に対する世界の関心が高まる中、チクングニアワクチンと治療薬の開発は、世界ヘルスへの投資において重要な位置を占めています。

世界のチクングニア熱市場成長の原動力は？

チクングニア熱市場の成長は、ベクターの生態、公衆衛生の緊急性、生物医学の革新に直接結びつくいくつかの要因によって牽引されています。第一に、気温の上昇、都市の混雑、水の停滞によるアカイエカ生息地の拡大が、世界の曝露リスクを増大させています。第二に、効果的な予防・治療法がないため、ワクチン、ポイントオブケア診断、ウイルス感染後の治療法に対するアンメットニーズが急増しています。新興感染症対策への公的・民間セクターの資金提供の増加は、特にチクングニアをターゲットとしたワクチンや抗ウイルスソリューションの急速な研究開発を促進しています。診断の面では、アジア、アフリカ、ラテンアメリカで疾病監視プログラムが強化されるのに伴い、迅速で手頃な価格の、現場展開可能なツールに対する需要が高まっています。最終用途としては、病院、軍の衛生局、旅行診療所、政府の疾病管理機関が、診断キットや将来のワクチンの主要な消費者として台頭してきています。さらに、旅行者の意識の高まりやデジタル情報キャンペーンは、蚊よけ剤の使用やワクチンへの関心など、積極的な疾病予防に向けた消費者行動に影響を与えています。これらの要因が相まって、チクングニア関連の診断薬、治療薬、予防ソリューションは世界的にダイナミックな高成長を遂げています。

セグメント

診断（ELISAベースのアッセイ診断、血清学的検査診断、ウイルス学的検査診断）、治療タイプ（アロパシー治療、ホメオパシー治療、アーユルヴェーダ治療、その他の治療タイプ）、エンドユーザー（病院・診療所エンドユーザー、外来手術センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • Aurobindo Pharma
  • Bharat Biotech
  • Bavarian Nordic
  • BioCryst Pharmaceuticals
  • BioNTech SE
  • Emergent BioSolutions
  • Eubiologics Co., Ltd.
  • GlaxoSmithKline（GSK）
  • Indian Immunologicals Ltd.
  • Inovio Pharmaceuticals
  • Instituto Butantan
  • Medigen Vaccine Biologics Corp.
  • Moderna, Inc.
  • MSD（Merck & Co., Inc.）
  • PaxVax（acquired by Emergent）
  • Sanofi
  • Takeda Pharmaceutical Company Ltd.
  • Themis Bioscience（a Merck company）
  • Valneva SE
  • Zydus Lifesciences（Cadila）

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36510

Global Chikungunya Fever Market to Reach US$670.7 Million by 2030

The global market for Chikungunya Fever estimated at US$478.1 Million in the year 2024, is expected to reach US$670.7 Million by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. ELISA based Assays Diagnosis, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$406.8 Million by the end of the analysis period. Growth in the Serological Tests Diagnosis segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$130.3 Million While China is Forecast to Grow at 9.3% CAGR

The Chikungunya Fever market in the U.S. is estimated at US$130.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$136.7 Million by the year 2030 trailing a CAGR of 9.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Chikungunya Fever Market - Key Trends & Drivers Summarized

Why Is Chikungunya Fever Resurging as a Major Public Health Challenge?

Chikungunya fever, once considered a sporadic tropical illness, has re-emerged in recent years as a major global health concern due to the rapid spread of the Aedes mosquito vector and rising global temperatures. Originally limited to parts of Africa and Asia, outbreaks have now been reported across South America, the Caribbean, and even parts of Europe and the U.S. This expanding geographic footprint is largely attributable to urbanization, increased global travel, and climate change-factors that facilitate both the transmission of the virus and the year-round survival of mosquito populations. Chikungunya fever, characterized by high fever, joint pain, fatigue, and rashes, can lead to chronic arthritic symptoms that linger for months, particularly in older adults. While mortality rates are low, the disease burden is significant in terms of lost productivity, healthcare costs, and long-term morbidity. Public health systems in affected regions are under growing pressure to ramp up surveillance, mosquito control programs, and public awareness campaigns. As the frequency and scale of outbreaks increase, the urgency around diagnostics, therapeutics, and vaccine development is intensifying across the global health ecosystem.

Are Diagnostic and Surveillance Innovations Enhancing Disease Management?

Yes, diagnostic and epidemiological advancements are beginning to transform the chikungunya fever landscape. Traditional diagnosis based on clinical symptoms and serology often overlaps with diseases like dengue and Zika, making accurate identification a persistent challenge. However, molecular diagnostics such as RT-PCR are now being employed more widely, offering precise detection in the early, viremic phase of the disease. Additionally, the development of point-of-care tests and multiplex assays capable of distinguishing chikungunya from other arboviruses is improving case management and resource allocation in outbreak settings. Geographic information systems (GIS), AI-driven predictive modeling, and drone-based mosquito surveillance are also being used by governments and NGOs to identify hotspots and anticipate outbreaks before they spiral. In endemic areas, mobile health (mHealth) platforms are helping to track symptom onset, treatment efficacy, and patient follow-ups, enhancing both patient care and data collection. As digital health infrastructure improves in low- and middle-income countries, these innovations are likely to become even more critical in timely intervention and containment efforts, particularly in resource-constrained settings.

How Are Vaccine Development and Therapeutic Research Shaping Market Prospects?

The absence of a licensed vaccine or specific antiviral treatment for chikungunya has spurred a global race among biotech firms, universities, and public-private partnerships to fill this critical gap. Several vaccine candidates are currently in various stages of development, with a few in Phase III clinical trials-some utilizing traditional inactivated platforms, others leveraging cutting-edge technologies like virus-like particles (VLPs) and mRNA. The Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO are actively supporting fast-track development and regulatory pathways, anticipating growing global demand for preventive measures. On the therapeutics front, research is ongoing into repurposing anti-inflammatory and antiviral drugs, while monoclonal antibody therapies are being explored for high-risk patients. Botanical and natural product research, particularly in endemic regions, is also contributing to alternative symptom management approaches. Once a viable vaccine is approved, government immunization programs and global health organizations are expected to drive mass adoption, especially in high-burden regions. With growing global interest in pandemic preparedness and viral outbreak response, chikungunya vaccine and therapeutic development is now firmly in the spotlight of global health investment.

What’s Driving Growth in the Chikungunya Fever Market Worldwide?

The growth in the chikungunya fever market is driven by several factors directly tied to vector ecology, public health urgency, and biomedical innovation. First, the expansion of Aedes mosquito habitats due to rising temperatures, urban crowding, and water stagnation is increasing global exposure risk. Second, the absence of effective preventive and curative solutions has created an urgent unmet need for vaccines, point-of-care diagnostics, and post-viral treatment modalities. Increased public and private sector funding in emerging infectious disease preparedness is catalyzing rapid R&D in vaccines and antiviral solutions specifically targeting chikungunya. On the diagnostic front, demand for rapid, affordable, and field-deployable tools is growing in tandem with intensified disease surveillance programs across Asia, Africa, and Latin America. In terms of end-use, hospitals, military health departments, travel clinics, and government disease control agencies are emerging as primary consumers of diagnostic kits and future vaccines. Additionally, heightened awareness among travelers and digital information campaigns are influencing consumer behavior toward proactive disease prevention, such as mosquito repellent use and vaccine interest. Together, these drivers are creating a dynamic, high-growth landscape for chikungunya-related diagnostics, therapeutics, and prevention solutions globally.

SCOPE OF STUDY:

The report analyzes the Chikungunya Fever market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis (ELISA based Assays Diagnosis, Serological Tests Diagnosis, Virological Tests Diagnosis); Treatment Type (Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment, Other Treatment Types); End-Use (Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Aurobindo Pharma
  • Bharat Biotech
  • Bavarian Nordic
  • BioCryst Pharmaceuticals
  • BioNTech SE
  • Emergent BioSolutions
  • Eubiologics Co., Ltd.
  • GlaxoSmithKline (GSK)
  • Indian Immunologicals Ltd.
  • Inovio Pharmaceuticals
  • Instituto Butantan
  • Medigen Vaccine Biologics Corp.
  • Moderna, Inc.
  • MSD (Merck & Co., Inc.)
  • PaxVax (acquired by Emergent)
  • Sanofi
  • Takeda Pharmaceutical Company Ltd.
  • Themis Bioscience (a Merck company)
  • Valneva SE
  • Zydus Lifesciences (Cadila)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Chikungunya Fever - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence in Tropical and Subtropical Regions Spurs Urgency in Vaccine Development
    • Climate Change and Urbanization Expand the Geographic Reach of Chikungunya-Carrying Mosquitoes
    • Increased Government Spending on Vector-Borne Disease Control Strengthens Public Health Infrastructure
    • Advances in Rapid Diagnostic Tools Accelerate Early Detection and Outbreak Containment
    • Surge in Travel to Endemic Areas Throws the Spotlight on Global Surveillance Programs
    • Lack of Approved Vaccines Creates Unmet Needs and Investment Opportunities
    • Increased Public Awareness Campaigns Drive Early Medical Intervention and Disease Management
    • Integration of Mobile Health Technologies in Disease Tracking Strengthens Preventive Efforts
    • Epidemiological Shifts in Viral Strains Create Demand for Adaptive Vaccine Platforms
    • Use of Genomic Tools in Vector Studies Supports Better Targeted Eradication Campaigns
    • Demand for Point-of-Care Testing Kits Sustains Market Growth in Remote and Rural Healthcare Settings
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chikungunya Fever Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chikungunya Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chikungunya Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Chikungunya Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for ELISA based Assays Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for ELISA based Assays Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for ELISA based Assays Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Serological Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Serological Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Serological Tests Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Virological Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Virological Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Virological Tests Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Allopathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Allopathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Allopathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Homeopathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Homeopathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Homeopathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Ayurveda Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Ayurveda Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Ayurveda Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • JAPAN
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • CHINA
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • EUROPE
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Chikungunya Fever by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Chikungunya Fever by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Chikungunya Fever by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • FRANCE
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • GERMANY
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Chikungunya Fever by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Chikungunya Fever by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Chikungunya Fever by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • INDIA
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Chikungunya Fever by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Chikungunya Fever by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Chikungunya Fever by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Chikungunya Fever by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Chikungunya Fever by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Chikungunya Fever by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • AFRICA
    • Chikungunya Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Chikungunya Fever by Diagnosis - ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Chikungunya Fever by Diagnosis - Percentage Breakdown of Value Sales for ELISA based Assays Diagnosis, Serological Tests Diagnosis and Virological Tests Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Chikungunya Fever by End-Use - Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Chikungunya Fever by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Chikungunya Fever by Treatment Type - Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Chikungunya Fever by Treatment Type - Percentage Breakdown of Value Sales for Allopathy Treatment, Homeopathy Treatment, Ayurveda Treatment and Other Treatment Types for the Years 2014, 2025 & 2030

IV. COMPETITION